Clinical trial · no report yet · Phase 2

NIMBUS

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

NCT03789110 ↗
Active, not recruiting
Dana-Farber Cancer Institute
Standard

We haven't built an HCP commentary report on NIMBUS (nivolumab plus ipilimumab in hypermutated HER2-negative metastatic breast cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on NIMBUS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
YouTube	8
X threads	7
Podcasts	3

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
Phase: Phase 2
Status: Active, not recruiting
Conditions: Breast Cancer
Interventions: Nivolumab; Ipilimumab
Arms: Nivolumab+Ipilimumab · Experimental
Enrollment: 30
Primary outcomes: Overall Response Rate of Nivolumab in Combination With Ipilimumab
Sponsor: Dana-Farber Cancer Institute with Bristol-Myers Squibb
Start: Mar 8, 2019
Primary completion: Sep 30, 2021
Results posted: Yes
Registry record: NCT03789110 · updated Apr 28, 2026

Publications

linked from the registry

Barroso-Sousa R, Zanudo JGT, Li T, Reddy SM, Emens LA, Kuntz TM, Silva CAC, AlDubayan SH, Chu H, Overmoyer B, Lange P, DiLullo MK, Montesion M, Kasparian J, Hughes ME, Attaya V, Basta A, Lin NU, Tayob N, Jeselsohn R, Mittendorf EA, Tolaney SM. Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS). Nat Commun. 2025 May 13;16(1):4430. doi: 10.1038/s41467-025-59695-1. PubMed 40360544